Access count of this item: 4

Files in This Item:
File Description SizeFormat 
CIRCULATIONAHA.119.040167.pdf379.48 kBAdobe PDFView/Open
Title: Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk
Authors: Urban, Philip
Mehran, Roxana
Colleran, Roisin
Angiolillo, Dominick J.
Byrne, Robert A.
Capodanno, Davide
Cuisset, Thomas
Cutlip, Donald
Eerdmans, Pedro
Eikelboom, John
Farb, Andrew
Gibson, C. Michael
Gregson, John
Haude, Michael
James, Stefan K.
Kim, Hyo-Soo
Kimura, Takeshi
Konishi, Akihide
Laschinger, John
Leon, Martin B.
Magee, P.F. Adrian
Mitsutake, Yoshiaki
Mylotte, Darren
Pocock, Stuart
Price, Matthew J.
Rao, Sunil V.
Spitzer, Ernest
Stockbridge, Norman
Valgimigli, Marco
Varenne, Olivier
Windhoevel, Ute
Yeh, Robert W.
Krucoff, Mitchell W.
Morice, Marie-Claude
Author's alias: 木村, 剛
Issue Date: 16-Jul-2019
Publisher: Ovid Technologies (Wolters Kluwer Health)
Journal title: Circulation
Volume: 140
Issue: 3
Start page: 240
End page: 261
Abstract: Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention–related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to complement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing percutaneous coronary intervention.
Rights: © 2019 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
URI: http://hdl.handle.net/2433/244323
DOI(Published Version): 10.1161/CIRCULATIONAHA.119.040167
PubMed ID: 31116032
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.